TY - JOUR
T1 - 10 good reasonswhy adrenal vein sampling is the preferredmethod for referring primary aldosteronism patients for adrenalectomy
AU - Rossi, Gian Paolo
AU - Mulatero, Paolo
AU - Satoh, Fumitoshi
N1 - Funding Information:
The current study was supported by the COST BM1301 – Aldosterone and Mineralocorticoid Receptor (ADMIRE) EU program (to G.P.R.) and by F.O.R.I.C.A. The Foundation fOr advanced Research In hypertension and Cardiovascular disease to G.P.R.
Publisher Copyright:
© 2018 Wolters Kluwer Health, Inc.
PY - 2019/3
Y1 - 2019/3
N2 - Nowadays most patients diagnosed with surgically curable primary aldosteronism have small or micro aldosteroneproducing adenoma or unilateral micronodular hyperplasia, which are undetectable with available imaging technologies. Therefore, a negative imaging test by no means excludes unilateral primary aldosteronism. Moreover, about 10% of the subjects above the age of 35 years have nonfunctioning adrenal tumors, regardless of being hypertensive or not, with a prevalence that raises with aging. Hence, the finding of an adrenal mass at imaging does not reliably detect the culprit of primary aldosteronism. On the other hand, when primary aldosteronism patients are selected for adrenalectomy on the basis of demonstration of lateralized aldosterone excess at adrenal vein sampling (AVS), close to 100% are biochemically cured from the hyperaldosteronism, about 45% are cured of arterial hypertension and an additional 52% are markedly improved in terms of blood pressure control. By contrast, patients referred for surgery based on imaging alone often fail to reach these successful outcomes, indicating that surgery was unnecessary or, even worse, performed on the wrong side. For these reasons, and because of the lack of accurate and widely available alternative methods, all current guidelines recommend that AVS be offered to all primary aldosteronism patients with only few exceptions, mainly in patients unable or unwilling to undergo surgery and those with germ-line mutations causing familial primary aldosteronism. The main argument against systematic use of AVS entails its suboptimal performance, partly justified by its intrinsic technical difficulty, and its limited availability. This led to propose skipping AVS strategies for predicting surgically curable primary aldosteronism, but success has been inconsistent. The most urgent standing issue is, therefore, not to find loopholes to avoid AVS, but rather to improve its use, which means improving the rate of AVS success, through formal training of interventionists, selection of appropriate cutoffs and exploitation of a standardized procedure.
AB - Nowadays most patients diagnosed with surgically curable primary aldosteronism have small or micro aldosteroneproducing adenoma or unilateral micronodular hyperplasia, which are undetectable with available imaging technologies. Therefore, a negative imaging test by no means excludes unilateral primary aldosteronism. Moreover, about 10% of the subjects above the age of 35 years have nonfunctioning adrenal tumors, regardless of being hypertensive or not, with a prevalence that raises with aging. Hence, the finding of an adrenal mass at imaging does not reliably detect the culprit of primary aldosteronism. On the other hand, when primary aldosteronism patients are selected for adrenalectomy on the basis of demonstration of lateralized aldosterone excess at adrenal vein sampling (AVS), close to 100% are biochemically cured from the hyperaldosteronism, about 45% are cured of arterial hypertension and an additional 52% are markedly improved in terms of blood pressure control. By contrast, patients referred for surgery based on imaging alone often fail to reach these successful outcomes, indicating that surgery was unnecessary or, even worse, performed on the wrong side. For these reasons, and because of the lack of accurate and widely available alternative methods, all current guidelines recommend that AVS be offered to all primary aldosteronism patients with only few exceptions, mainly in patients unable or unwilling to undergo surgery and those with germ-line mutations causing familial primary aldosteronism. The main argument against systematic use of AVS entails its suboptimal performance, partly justified by its intrinsic technical difficulty, and its limited availability. This led to propose skipping AVS strategies for predicting surgically curable primary aldosteronism, but success has been inconsistent. The most urgent standing issue is, therefore, not to find loopholes to avoid AVS, but rather to improve its use, which means improving the rate of AVS success, through formal training of interventionists, selection of appropriate cutoffs and exploitation of a standardized procedure.
KW - Adrenal vein sampling
KW - Aldosterone
KW - Aldosteronism
KW - Diagnosis
KW - Subtyping
UR - http://www.scopus.com/inward/record.url?scp=85060956030&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85060956030&partnerID=8YFLogxK
U2 - 10.1097/HJH.0000000000001939
DO - 10.1097/HJH.0000000000001939
M3 - Review article
C2 - 30431526
AN - SCOPUS:85060956030
SN - 0263-6352
VL - 37
SP - 603
EP - 611
JO - Journal of Hypertension
JF - Journal of Hypertension
IS - 3
ER -